Diabetic ketoacidosis, sodium glucose transporter-2 inhibitors and the kidney

被引:29
作者
Palmer, Biff F. [1 ]
Clegg, Deborah J. [2 ]
Taylor, Simeon I. [3 ]
Weir, Matthew R. [4 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX USA
[2] Cedars Sinai Med Ctr, Biomed Res Dept, Diabet & Obes Res Div, Beverly Hills, CA USA
[3] Univ Maryland, Sch Med, Dept Med, Div Endocrinol Diabet & Nutr, Baltimore, MD USA
[4] Univ Maryland, Sch Med, Dept Med, Div Nephrol, Baltimore, MD 21201 USA
关键词
Diabetic ketoacidosis; Sodium glucose transporter 2 inhibitors; Kidney; Glucose; Transport maximum; KETONE-BODIES; RENAL AMMONIAGENESIS; SGLT2; INHIBITORS; FATTY-ACIDS; SECRETION; CANAGLIFLOZIN; DAPAGLIFLOZIN; STARVATION; OXIDATION; MELLITUS;
D O I
10.1016/j.jdiacomp.2016.05.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic ketoacidosis is a serious metabolic condition that may occur in patients with either Type 1 or Type 2 diabetes. The accumulation of ketoacids in the serum is a consequence of insulin deficiency and glucagon excess. Sodium Glucose Transporter 2 (SGLT2) inhibitors are novel therapeutic treatments for improving glucose homeostasis in patients with diabetes. Through reductions in glucose reabsorption by the kidney, they lower serum glucose in patients with Type 2 diabetes and they improve glucose control whether used alone or in combination with other therapies. Mechanistically, these drugs increase serum ketoacids and increase glucagon production, which in some individuals, can lead to formation of diabetic ketoacidosis. This review will first focus in how the kidney normally handles ketoacids, and second will discuss how the SGLT2 inhibitors affect the kidney in such a way so as to enhance the risk for development of ketoacidosis in susceptible individuals. (C) 2016 Elsevier Inc. All rights reserved.
引用
收藏
页码:1162 / 1166
页数:5
相关论文
共 33 条
[21]   Electrolyte and Acid-Base Disturbances in Patients with Diabetes Mellitus [J].
Palmer, Biff F. ;
Clegg, Deborah J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (06) :548-559
[22]   SLC22, SLC44, and SLC47 Transporters-Organic Anion and Cation Transporters: Molecular and Cellular Properties [J].
Pelis, Ryan M. ;
Wright, Stephen H. .
EXCHANGERS, 2014, 73 :233-261
[23]   Cellular and subcellular distribution of monocarboxylate transporters in cultured brain cells and in the adult brain [J].
Pellerin, L ;
Halestrap, AP ;
Pierre, K .
JOURNAL OF NEUROSCIENCE RESEARCH, 2005, 79 (1-2) :55-64
[24]   Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition [J].
Peters, Anne L. ;
Buschur, Elizabeth O. ;
Buse, John B. ;
Cohan, Pejman ;
Diner, Jamie C. ;
Hirsch, Irl B. .
DIABETES CARE, 2015, 38 (09) :1687-1693
[25]   Oxidation of Fatty Acids Is the Source of Increased Mitochondrial Reactive Oxygen Species Production in Kidney Cortical Tubules in Early Diabetes [J].
Rosca, Mariana G. ;
Vazquez, Edwin J. ;
Chen, Qun ;
Kerner, Janos ;
Kern, Timothy S. ;
Hoppel, Charles L. .
DIABETES, 2012, 61 (08) :2074-2083
[26]   Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors [J].
Rosenstock, Julio ;
Ferrannini, Ele .
DIABETES CARE, 2015, 38 (09) :1638-1642
[27]   RENAL CONSERVATION OF KETONE-BODIES DURING STARVATION [J].
SAPIR, DG ;
OWEN, OE .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1975, 24 (01) :23-33
[28]   EFFECT OF KETONE INFUSIONS ON AMINO-ACID AND NITROGEN-METABOLISM IN MAN [J].
SHERWIN, RS ;
HENDLER, RG ;
FELIG, P .
JOURNAL OF CLINICAL INVESTIGATION, 1975, 55 (06) :1382-1390
[29]  
Singh Awadhesh Kumar, 2015, Indian J Endocrinol Metab, V19, P722, DOI 10.4103/2230-8210.167554
[30]   Glucagon Regulates Hepatic Kisspeptin to Impair Insulin Secretion [J].
Song, Woo-Jin ;
Mondal, Prosenjit ;
Wolfe, Andrew ;
Alonso, Laura C. ;
Stamateris, Rachel ;
Ong, Benny W. T. ;
Lim, Owen C. ;
Yang, Kil S. ;
Radovick, Sally ;
Novaira, Horacio J. ;
Farber, Emily A. ;
Farber, Charles R. ;
Turner, Stephen D. ;
Hussain, Mehboob A. .
CELL METABOLISM, 2014, 19 (04) :667-681